Abstract
A multinational collaborative effort aimed to develop a new set of criteria for macrophage activation syndrome (MAS) complicating systemic juvenile idiopathic arthritis (sjia) is ongoing. The data-collection phase of the project has been recently completed
Highlights
Pediatric Rheumatology European Society (PReS)-FINAL-2141: Clinical features, therapeutic interventions and outcome of 362 patients with macrophage activation syndrome enrolled in a multinational survey
A multinational collaborative effort aimed to develop a new set of criteria for macrophage activation syndrome (MAS) complicating systemic juvenile idiopathic arthritis is ongoing
362 patients with sjia-associated MAS were entered in the study website by 95 investigators (78.2% paediatric rheumatologists, 21.8% paediatric hemato-oncologists) from 33 countries. 208 patients (57.5%) were females
Summary
PReS-FINAL-2141: Clinical features, therapeutic interventions and outcome of 362 patients with macrophage activation syndrome enrolled in a multinational survey Introduction A multinational collaborative effort aimed to develop a new set of criteria for macrophage activation syndrome (MAS) complicating systemic juvenile idiopathic arthritis (sjia) is ongoing. Objectives To describe the demographic, clinical, laboratory, and histopathologic features, therapeutic interventionsand outcome of 362 children with MAS collected in the study. Methods Patient data were collected retrospectively in a web-based database, developed and handled at the coordinating centre
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.